| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Virology |
Department of Otolaryngology, Long Island Jewish Medical Center, The Long Island Campus of the Albert Einstein College of Medicine, New Hyde Park, New York 11040
Laryngeal papillomas are benign, human papillomavirus-induced hyperplastic tumors of the respiratory tract. They are characterized by overexpression of the epidermal growth factor receptor, constitutive activation of mitogen-activated protein kinase, a low proliferative rate, and defects in differentiation. We have now found that phosphoinositol 3-kinase (PI 3-K) activity is significantly increased in papilloma tissue. However, phosphorylated Akt (also known as protein kinase B), a downstream effector of PI 3-K, is reduced when compared with normal tissue. The ratio of activated Akt to total Akt is much lower in papillomas than in normal laryngeal tissue, suggesting decreased Akt activation. PTEN/MMAC1 is a tumor suppressor that dephosphorylates phosphatidylinositol 3,4,5-triphosphate, an intermediate in the PI 3-K/Akt signaling pathway. We have found that PTEN protein is overexpressed in laryngeal papillomas when compared with normal laryngeal tissues. On the basis of reverse transcription-PCR analysis, PTEN mRNA is more abundant in papillomas, suggesting transcriptional up-regulation. We postulate that negative regulation of the PI 3-K/Akt pathway by PTEN may modulate the effects of the hyperactive epidermal growth factor receptor/mitogen-activated protein kinase pathway, contributing to the low proliferation and dysfunctional differentiation of laryngeal papillomas.
This article has been cited by other articles:
![]() |
R. Wu, A. L. Abramson, M. J. Shikowitz, A. J. Dannenberg, and B. M. Steinberg Epidermal Growth Factor-Induced Cyclooxygenase-2 Expression Is Mediated through Phosphatidylinositol-3 Kinase, Not Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase, in Recurrent Respiratory Papillomas Clin. Cancer Res., September 1, 2005; 11(17): 6155 - 6161. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. C. Fausch, L. M. Fahey, D. M. Da Silva, and W. M. Kast Human Papillomavirus Can Escape Immune Recognition through Langerhans Cell Phosphoinositide 3-Kinase Activation J. Immunol., June 1, 2005; 174(11): 7172 - 7178. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Sun and B. M. Steinberg PTEN is a negative regulator of STAT3 activation in human papillomavirus-infected cells J. Gen. Virol., June 1, 2002; 83(7): 1651 - 1658. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Vancurova, R. Wu, V. Miskolci, and S. Sun Increased p50/p50 NF-{kappa}B Activation in Human Papillomavirus Type 6- or Type 11-Induced Laryngeal Papilloma Tissue J. Virol., February 1, 2002; 76(3): 1533 - 1536. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Gupta, S. Stuffrein, R. Plattner, M. Tencati, C. Gray, Y. E. Whang, and E. J. Stanbridge Role of Phosphoinositide 3-Kinase in the Aggressive Tumor Growth of HT1080 Human Fibrosarcoma Cells Mol. Cell. Biol., September 1, 2001; 21(17): 5846 - 5856. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Torres and R. Pulido The Tumor Suppressor PTEN Is Phosphorylated by the Protein Kinase CK2 at Its C Terminus. IMPLICATIONS FOR PTEN STABILITY TO PROTEASOME-MEDIATED DEGRADATION J. Biol. Chem., January 5, 2001; 276(2): 993 - 998. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |